120 related articles for article (PubMed ID: 2767108)
61. Serum CA-125 in women with endometriosis and chronic pelvic pain.
Pittaway DE; Douglas JW
Fertil Steril; 1989 Jan; 51(1):68-70. PubMed ID: 2910718
[TBL] [Abstract][Full Text] [Related]
62. Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
Mogensen O; Mogensen B; Jakobsen A
Br J Cancer; 1990 Feb; 61(2):327-9. PubMed ID: 2310684
[TBL] [Abstract][Full Text] [Related]
63. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.
Jacobs I; Oram D; Fairbanks J; Turner J; Frost C; Grudzinskas JG
Br J Obstet Gynaecol; 1990 Oct; 97(10):922-9. PubMed ID: 2223684
[TBL] [Abstract][Full Text] [Related]
64. [Value of color Doppler ultrasonography, contrast-enhanced ultrasound and serum CA-125 detection in differential diagnosis of ovarian masses].
Zhou Q; Liu BL; Jiang J; Lei XY
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct; 29(10):2007-9. PubMed ID: 19861251
[TBL] [Abstract][Full Text] [Related]
65. [CA 125 in the diagnosis and evaluation of the efficacy of the treatment of cancer of the ovaries].
Sagan DL; Chebotareva ED; Evtushenko GV
Med Radiol (Mosk); 1989 Jun; 34(6):39-42. PubMed ID: 2739519
[TBL] [Abstract][Full Text] [Related]
66. Comparison of Doppler with two-dimensional sonography and CA 125 for prediction of malignancy of pelvic masses.
Schneider VL; Schneider A; Reed KL; Hatch KD
Obstet Gynecol; 1993 Jun; 81(6):983-8. PubMed ID: 8497367
[TBL] [Abstract][Full Text] [Related]
67. The clinical significance of thrombocytosis in women presenting with a pelvic mass.
Chalas E; Welshinger M; Engellener W; Chumas J; Barbieri R; Mann WJ
Am J Obstet Gynecol; 1992 Mar; 166(3):974-7. PubMed ID: 1550175
[TBL] [Abstract][Full Text] [Related]
68. Comparison of ultrasound score, CA125, menopausal status, and risk of malignancy index in differentiating between benign and borderline or malignant ovarian tumors.
Leelahakorn S; Tangjitgamol S; Manusirivithaya S; Thongsuksai P; Jaroenchainon P; Jivangkul C
J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S22-30. PubMed ID: 17718292
[TBL] [Abstract][Full Text] [Related]
69. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
[TBL] [Abstract][Full Text] [Related]
70. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.
Yedema CA; Kenemans P; Wobbes T; Thomas CM; Bon GG; Mulder C; Voorhorst FJ; Verstraeten AA; van Kamp GJ; Hilgers J
Tumour Biol; 1992; 13(1-2):18-26. PubMed ID: 1589694
[TBL] [Abstract][Full Text] [Related]
71. Comparison between serum CA 125 and CA 19-9 assays and tissular OC 125 and 1116NS 19-9 reactivity in malignant and benign ovarian tumors.
Gadducci A; Ciancia EM; Malagnino G; De Luca F; Campani D; Ferdeghini M; Facchini V; Pingitore R; Fioretti P
Eur J Gynaecol Oncol; 1992; 13(4):346-54. PubMed ID: 1516586
[TBL] [Abstract][Full Text] [Related]
72. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526
[TBL] [Abstract][Full Text] [Related]
73. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
Bast RC; Knauf S; Epenetos A; Dhokia B; Daly L; Tanner M; Soper J; Creasman W; Gall S; Knapp RC
Cancer; 1991 Oct; 68(8):1758-63. PubMed ID: 1913520
[TBL] [Abstract][Full Text] [Related]
74. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
Onsrud M; Shabana A; Austgulen R
Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
[TBL] [Abstract][Full Text] [Related]
75. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
[TBL] [Abstract][Full Text] [Related]
76. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.
Van Calster B; Timmerman D; Bourne T; Testa AC; Van Holsbeke C; Domali E; Jurkovic D; Neven P; Van Huffel S; Valentin L
J Natl Cancer Inst; 2007 Nov; 99(22):1706-14. PubMed ID: 18000221
[TBL] [Abstract][Full Text] [Related]
77. [Role of pulsed color Doppler in the presurgical evaluation of pelvic masses].
Salle B; Gaucherand P; Ecochard R; Rudigoz RC
J Gynecol Obstet Biol Reprod (Paris); 1995; 24(3):234-40. PubMed ID: 7622769
[TBL] [Abstract][Full Text] [Related]
78. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
Lycke M; Kristjansdottir B; Sundfeldt K
Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
[TBL] [Abstract][Full Text] [Related]
79. Serum LDH and CA-125: Markers for Diagnosis of Ovarian Malignancy.
Deeba F; Khatun S; Alam MM; Shahida SM
Mymensingh Med J; 2015 Apr; 24(2):334-40. PubMed ID: 26007262
[TBL] [Abstract][Full Text] [Related]
80. Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology.
Van Holsbeke C; Van Belle V; Leone FP; Guerriero S; Paladini D; Melis GB; Greggi S; Fischerova D; De Jonge E; Neven P; Bourne T; Valentin L; Van Huffel S; Timmerman D
Ultrasound Obstet Gynecol; 2010 Jul; 36(1):81-7. PubMed ID: 20217895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
